Asia, Neglected Diseases Score Big In Nobel Prize Win
This article was originally published in PharmAsia News
Health campaigners and organizations working in the area of drugs for neglected diseases have hailed the Nobel Prize awarded to three researchers in the field, but the move also highlights shortcomings and research gaps.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.